Intellia Therapeutics Inc is at the forefront of genome editing, pioneering the development of treatments with the potential to cure diseases. Their work includes groundbreaking in vivo programs like NTLA-2001, targeting transthyretin amyloidosis, and others aimed at hereditary angioedema and alpha-1 antitrypsin deficiency. Beyond these, Intellia is exploring engineered cell therapies for cancer and autoimmune diseases, leveraging advanced CRISPR/Cas9 technology. Partnerships with leading biotech firms enhance their efforts in hemophilia and CAR-T cell therapies, underscoring their commitment to revolutionizing medicine. Founded in 2014, Intellia's home base is in Cambridge, Massachusetts.
Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly…
Invasive species represent a $5.4 trillion global problem, with U.S. economic impact alone exceeding $500 billion annually. That’s according to Ben Lamm, CEO of Colossal Biosciences. On episode 245 of the Moonshots…
Investors have become quite familiar with the Magnificent Seven, the group of tech giants that reshaped markets with their dominance in AI, cloud computing, and digital ecosystems by driving unprecedented growth. Initially…
Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an annualized growth rate of approximately 63% over a decade. This level…
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Vir Biotechnology.
Wednesday's top analyst upgrades and downgrades included Academy Sports and Outdoors, Asana, Charles Schwab, Estee Lauder, General Electric, GitLab, Home Depot, Match, Ovintiv, SoFi Technologies and United Airlines.
Wednesday's top analyst upgrades and downgrades included Amazon.com, Blackstone, Caesars Entertainment, Dollar Tree, DraftKings, GlobalFoundries, IBM, Lyft, Marathon Oil, McDonald's, Palo Alto Networks, Starbucks, Target, Toast and ZScaler.
Thursday’s top analyst upgrades and downgrades included AutoZone, CrowdStrike, Estee Lauder, Morgan Stanley, Nvidia and Western Digital.
Friday's top analyst upgrades and downgrades included Acadia Pharmaceuticals, Accenture, Amgen, AutoZone, Azek, Boeing, Dollar General, Etsy, Fidelity National Information Services, FedEx, NexTier Oilfield Solutions, S&P Global, Unity Software and Warner Bros.…
Tuesday's top analyst upgrades and downgrades included Apple, Continental Resources, Bilibili, Eaton, Hershey, Meta Platforms, Nio, NOV, PayPal and Southern Company.
Friday afternoon's analyst upgrades and downgrades included Barrick Gold, Canadian National Railway, Community Health Systems, Editas Medicine, Intellia Therapeutics, Newmont and Salesforce.com.
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
Friday's top analyst upgrades and downgrades included Biogen, CME, Dropbox, DocuSign, Nvidia, Ping Identity, Signet Jewelers and Tilray.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Etsy, Fate Therapeutics, Intellia, Ionis, Monster Beverage and more.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including Domino’s Pizza, Editas Medicine, Roblox, Teva Pharmaceutical Industries and U.S. Steel.
